Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D, Meadows HM, Cunningham D, Plowman PN, Hurman DC, Davidson N, Grieve R, Levine E, Glynne-Jones R. Sebag-Montefiore D, et al. Radiother Oncol. 2012 Aug;104(2):155-60. doi: 10.1016/j.radonc.2012.06.006. Epub 2012 Aug 1. Radiother Oncol. 2012. PMID: 22857859 Clinical Trial.
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, Ledermann J, Sebag-Montefiore D. Glynne-Jones R, et al. Among authors: meadows hm. Ann Oncol. 2014 Jul;25(7):1356-1362. doi: 10.1093/annonc/mdu147. Epub 2014 Apr 8. Ann Oncol. 2014. PMID: 24718885 Free article. Clinical Trial.
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. James RD, et al. Lancet Oncol. 2013 May;14(6):516-24. doi: 10.1016/S1470-2045(13)70086-X. Epub 2013 Apr 9. Lancet Oncol. 2013. PMID: 23578724 Clinical Trial.
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L; ACT II study group. Glynne-Jones R, et al. Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11. Lancet Oncol. 2017. PMID: 28209296 Free PMC article. Clinical Trial.
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D; ACT II Study Group. Glynne-Jones R, et al. Among authors: meadows hm. Ann Oncol. 2014 Aug;25(8):1616-22. doi: 10.1093/annonc/mdu188. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827136 Free article. Clinical Trial.
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial.
Glynne-Jones R, Meadows HM, Lopes A, Muirhead R, Sebag-Montefiore D, Adams R; ACTII study group. Glynne-Jones R, et al. Among authors: meadows hm. Ann Oncol. 2020 Oct;31(10):1376-1385. doi: 10.1016/j.annonc.2020.06.012. Epub 2020 Jun 30. Ann Oncol. 2020. PMID: 32619648 Free article. Clinical Trial.
"Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Glynne-Jones R, Sebag-Montefiore D, Adams R, McDonald A, Gollins S, James R, Northover JM, Meadows HM, Jitlal M; UKCCCR Anal Cancer Trial Working Party. Glynne-Jones R, et al. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1488-94. doi: 10.1016/j.ijrobp.2010.07.1995. Epub 2010 Oct 8. Int J Radiat Oncol Biol Phys. 2011. PMID: 20934265 Clinical Trial.
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. Glynne-Jones R, et al. Among authors: meadows h. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. doi: 10.1016/j.ijrobp.2007.12.012. Epub 2008 May 9. Int J Radiat Oncol Biol Phys. 2008. PMID: 18472366 Clinical Trial.
88 results